Screener
Becton, Dickinson and Company BDX BioPharma Systems — Research and development expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Becton, Dickinson and Company in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Becton, Dickinson and Company’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:34 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000010795-26-000026
| Three Months Ended March 31, 2026 / (Millions of dollars) | Medical / Essentials | Connected / Care | Bio Pharma / Systems | Interventional | Total |
|---|---|---|---|---|---|
| % of revenues | 50.7% | 43.7% | 53.6% | 31.6% | |
| Selling and administrative expense | 185 | 190 | 32 | 277 | 684 |
| % of revenues | 11.2% | 17.0% | 5.4% | 20.4% | |
| Research and development expense | 53 | 90 | 17 | 72 | 232 |
| % of revenues | 3.2% | 8.1% | 2.8% | 5.3% | |
| Other operating expense, net | — | 3 | — | — | 3 |
| % of revenues | — | 0.3% | — | — | |
| Segment Operating Income | $574 | $347 | $225 | $579 | $1,724 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Becton, Dickinson and Company's biopharma systems — research and development expense?
- Becton, Dickinson and Company (BDX) reported biopharma systems — research and development expense of $17M in Q1 2026.
- What does biopharma systems — research and development expense mean?
- This metric tracks the total investment in research and development activities specifically dedicated to the BioPharma Systems segment. These expenditures are critical for driving innovation in drug delivery technologies and maintaining a competitive product pipeline.
Ask your AI about Becton, Dickinson and Company's biopharma systems — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude